Recent Updates
Recently added Catalysts
BMRN Positive Sentiment Score: 75/100

BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a...

Key Takeaway: BioMarin Pharmaceutical Inc. will host a conference call and webcast on May 1, 2025, at 4:30 p.m. ET to discuss their first quarter financial results and provide a business update. Alexander Hardy, President and CEO, will lead the call. Interested parties can access the live audio through the investor section of the company's website, where a replay will also be available for a week. BioMarin is noted for its commitment to advancing treatments for rare genetic conditions.

Market Sentiment Analysis

POSITIVE FACTORS

  • BioMarin is demonstrating transparency by hosting a conference call to discuss financial results.
  • The company continues to innovate with a strong clinical and preclinical pipeline.
  • BioMarin has a proven track record with eight commercial therapies.

Full Press Release Details

SAN RAFAEL, Calif. , April 17, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that Alexander Hardy , President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, May 1, 2025 , at 4:30 p.m. ET to discuss first quarter 2025 financial results and provide a general business update.
Dial-in Number U.S. / Canada Dial-in Number: 888-596-4144 International Dial-in Number: 646-968-2525 Conference Call ID: 4327591
U.S. / Canada Replay Dial-in Number: 800-770-2030 International Replay Dial-in Number: 609-800-9909 Playback ID: 4327591
Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, https://investors.biomarin.com/ . A replay of the call will be archived on the site for one week following the call.
About BioMarin BioMarin is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient. The San Rafael, California -based company, founded in 1997, has a proven track record of innovation with eight commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin pursues treatments that offer new possibilities for patients and families around the world navigating rare or difficult-to-treat genetic conditions. To learn more, please visit www.biomarin.com .
Contacts:
Investors Media
Traci McCarty Marni Kottle
BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc.
(415) 455-7558 (650) 374-2803
SOURCE BioMarin Pharmaceutical Inc.

21 %

Frequently Asked Questions

When will BioMarin hold its financial results conference call?

BioMarin's conference call will be on May 1, 2025, at 4:30 p.m. ET.

How can I access the BioMarin conference call webcast?

The conference call webcast can be accessed on the BioMarin investor website.

What is BioMarin's focus as a biotechnology company?

BioMarin focuses on translating genetic discoveries into impactful medicines for patients.

What is BioMarin's company background?

Founded in 1997, BioMarin has a strong pipeline and eight commercial therapies.

Last updated: Apr 17, 2025